A Phase 4 interventional study of 1mg/mL ciclosporin in Keratitis, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Santen SAS · Phase 4, Interventional, and Treatment
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered once daily in dry eye disease (DED) patients with severe keratitis, as well as its safety and efficacy.
In this phase IV clinical trial the Month 3 visit assessments will be used to assess the efficacy (quality of vision and other parameters) and safety of IKERVIS® in DED patients with severe keratitis.
To assess the effect on the quality of vision of IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily in adult dry eye disease (DED) patients with severe keratitis over 3 months of treatment.
To assess the safety of DED patients with severe keratitis treated with IKERVIS® (1mg/mL ciclosporin) for 3 months.
Patient eligibility is determined according to the following criteria:
DED patients with persistent severe keratitis at the Screening and
Baseline Visits defined as the following:
Exclusion Criteria:
one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
Drug: 1mg/mL ciclosporin
IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
Also known as: IKERVIS®
Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3.
Spearman's coefficient of correlation will be calculated at Month 3 between the change from baseline of Corneal Fluorescein Staining (CFS) and respectively the change from baseline of Visual Maintenance Ratio (VRM).
Time frame: at month 3
| Milestone | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| Started | 17 |
| Completed | 16 |
| Not completed | 1 |
Spearman's coefficient of correlation will be calculated at Month 3 between the change from baseline of Corneal Fluorescein Staining (CFS) and respectively the change from baseline of Visual Maintenance Ratio (VRM).
| Spearman's coefficient of correlation | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3. | -0.7028 (-0.8797 to -0.3158) |
Collected over Adverse events were collected from the time of informed consent until the subject's participation in the study ended at Month 3.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IKERVIS® (1mg/mL Ciclosporin) Eye Drops | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Event | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| EYE IRRITATIONEye disorders | 3/17 |
| DRY EYEEye disorders | 2/17 |
| EYE BURNSEye disorders | 1/17 |
| EYELID OEDEMAEye disorders | 1/17 |
| PHOTOPHOBIAEye disorders | 1/17 |
| VISUAL ACUITY REDUCEDEye disorders | 1/17 |
| Age, Continuous(years) | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| Mean | 61.9 ± 12.7 |
| Sex: Female, Male(Participants) | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| Female | 13 |
| Male | 4 |
| Race and Ethnicity Not Collected(Participants) | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|
| Region of Enrollment(participants) | IKERVIS® (1mg/mL Ciclosporin) Eye Drops |
|---|---|
| France | 17 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen SAS